Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Vericiguat Clear all

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: Vericiguat (Verquvo, BAY1021189); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Metabolic Syndrome, Coronary Microvascular Dysfunction
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 35 Years to 85 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Heart Failure
Interventions: Vericiguat; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more

Conditions: Chronic Heart Failure With Preserved Ejection Fraction
Interventions: Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 29
States / cities: Beverly Hills, California • Carmichael, California • West Hills, California + 26 more

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: Vericiguat (BAY1021189) 5 mg; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 5
States / cities: Alexander City, Alabama • Richmond, Indiana • Baltimore, Maryland + 2 more

Conditions: Heart Failure, Left Ventricular Systolic Dysfunction
Interventions: Vericiguat tablet, Vericiguat suspension, Placebo tablet, Placebo suspension; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 29 Days to 17 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 20
States / cities: Los Angeles, California • Palo Alto, California • San Bernardino, California + 17 more

Conditions: Endothelial Dysfunction, Vascular Diseases, Kidney Injury, Brain Disease, Vascular Inflammation
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Heart Failure With Reduced Ejection Fraction
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 6,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 84
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 74 more

Conditions: Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions: Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Cardiac Dysfunction
Interventions: Vericiguat, Optimal medical therapy; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions: Vericiguat, Placebo; Drug
Lead sponsor: Josef Stehlik; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Salt Lake City, Utah

Search by objective public record fields.

An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

Impact of Vericiguat on Hemodynamics of Heart Failure

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation